A new experimental treatment called miv-cel has shown encouraging results in patients with stiff-person syndrome (SPS), a rare autoimmune disease affecting figures like Celine Dion. In a phase II trial with 26 participants, a single infusion of this cell therapy reduced stiffness and improved mobility and overall disability.
Miv-cel: cellular engineering to halt autoimmunity 🧬
Miv-cel is a therapy based on genetically modified T lymphocytes. These are designed to attack and eliminate autoreactive B cells that produce antibodies against the GAD65 protein, key in SPS. The trial showed that the single infusion not only reduced target antibodies but also improved clinical parameters such as muscle stiffness and walking ability. Adverse effects were manageable, with fever and fatigue being the most common.
Celine Dion, SPS, and science: finally some good news 🎤
While Celine Dion deals with SPS from the stage, scientists have been in labs trying not to hit a wrong note. And this time, the melody seems right: a single dose of miv-cel and patients move better than a backup singer lip-syncing. Of course, we'll have to wait for phase III to know if the treatment is a hit or just an encore that doesn't convince the audience.